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Background: Chronic kidney disease (CKD) patients present a complex interaction between the innate and
adaptive immune systems, in which immune activation (hypercytokinemia and acute-phase response) and immune
suppression (impairment of response to infections and poor development of adaptive immunity) coexist. In this
setting, circulating uremic toxins and microinflammation play a critical role. This condition, already present in the
last stages of renal damage, seems to be enhanced by the contact of blood with bioincompatible extracorporeal
hemodialysis (HD) devices. However, although largely described, the cellular machinery associated to the CKD- and
HD-related immune-dysfunction is still poorly defined. Understanding the mechanisms behind this important
complication may generate a perspective for improving patients outcome.
Methods: To better recognize the biological bases of the CKD-related immune dysfunction and to identify
differences between CKD patients in conservative (CKD) from those in HD treatment, we used an high-throughput
strategy (microarray) combined with classical bio-molecular approaches.
Results: Immune transcriptomic screening of peripheral blood mononuclear cells (1030 gene probe sets selected
by Gene-Ontology) showed that 275 gene probe sets (corresponding to 213 genes) discriminated 9 CKD patients
stage III-IV (mean ± SD of eGFR: 32.27±14.7 ml/min) from 17 HD patients (p < 0.0001, FDR = 5%). Seventy-one genes
were up- and 142 down-regulated in HD patients. Functional analysis revealed, then, close biological links among
the selected genes with a pivotal role of PTX3, IL-15 (up-regulated in HD) and HLA-G (down-regulated in HD).
ELISA, performed on an independent testing-group [11 CKD stage III-IV (mean ± SD of eGFR: 30.26±14.89 ml/min)
and 13 HD] confirmed that HLA-G, a protein with inhibition effects on several immunological cell lines including
natural killers (NK), was down-expressed in HD (p = 0.04). Additionally, in the testing-group, protein levels of
CX3CR1, an highly selective chemokine receptor and surface marker for cytotoxic effector lymphocytes, resulted
higher expressed in HD compared to CKD (p < 0.01).
Conclusion: Taken together our results show, for the first time, that HD patients present a different immune-
pattern compared to the un-dialyzed CKD patients. Among the selected genes, some of them encode for
important biological elements involved in proliferation/activation of cytotoxic effector lymphocytes and in the
immune-inflammatory cellular machinery. Additionally, this study reveals new potential diagnostic bio-markers and
therapeutic targets.* Correspondence: gianluigi.zaza@univr.it
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Chronic kidney disease (CKD) is a major and growing
challenge for health care systems. The prevalence rates
of CKD appear to be increasing globally [1-3] primarily
as a consequence of the augmented incidence of
diabetes, hypertension, and aging population [4-6].
An international medical consensus has classified
CKD into five stages according to the glomerular filtra-
tion rate (GFR) [7]. During the progression of renal
damage, CKD patients undergo considerable metabolic
changes, enhancement of inflammation/oxidative stress
and significant development of several immunological
alterations [8-11].
In particular, it has been well described that CKD
patients develop a complex interaction between the in-
nate and adaptive systems, in which immune activation
(hypercytokinemia and acute-phase response) and im-
mune suppression (impairment of response to infections
and poor development of adaptive immunity) coexist
[12]. In this setting, circulating uremic toxins and
microinflammation play a critical role [13,14]. During in-
flammation, vasodilatation, vascular permeability, move-
ment of inflammatory cells, and activation of cells of the
immune system are increased [15,16].
In last stage of CKD (end stage renal disease), the
enhancement of these clinical complications requires a
rapid start of renal replacement therapies (RRTs) to en-
sure patients survival. Among RRTs, hemodialysis (HD)
represents the most advanced form of artificial renal
support. This method, through an extracorporeal circuit,
removes waste products generated from normal meta-
bolic processes, uremic toxins and normalizes body fluid
and electrolytes [17].
Over the past five decades, the dialysis devices and
membranes (dialysis filters) used for the treatment of
CKD have continuously evolved and their basic structure
has been modified to improve the biocompatibility
profile of the material. This has led to the more effective
removal of molecules involved in the development of
complications associated with dialysis treatment [18-20].
Thus, the elaboration of biocompatible materials and the
introduction of more effective pharmacological strategy
to reduce microinflammation and oxidative stress are
great challenges in nephrology.
However, although, during HD, we assist to an im-
provement of clinical status, patients undergoing this
treatment still present important biological/biochemical
alterations and they may develop serious clinical compli-
cations, such as amyloid arthropathy, bone loss diseases
and accelerated atherosclerosis [21,22].
All these complications seem to be closely related to
two key factors: a defective immune system function and
continuous non-specific immune cell stimulation by
dialysis devices [13].In particular, several literature reports [10,23-25]
demonstrated that HD patients present multifactorial
biological and cellular dysfunctions including: activation
of mononuclear cells, complement fixation, cytokine
synthesis and release, reactive oxygen species (ROS), car-
bonyl stress and nitric oxide (NO) synthesis. However,
HD may have positive effects on the immune-system. In
particular, Kaul et al. have reported that initiation of HD
led to a significant improvement of in vitro T-cell pro-
liferation [26].
In the last years, several different therapeutic interven-
tions have been proposed to prevent or at least limit
HD-related cellular/biological alterations, including the
use of biocompatible membranes that could limit the
complement activation and cytokine release; the acti-
vation of high flux dialysis or hemofiltration that
would reduce the circulating levels of complement-
activating molecules and the accurate use of sterile
water [18,27]. However, at the moment, we are still far
from a total development of full biocompatible dialysis
procedure.
The present study, utilizing an innovative transcriptomic
approach combined to classical molecular methodologies,
has been undertaken to better clarify biological me-
chanisms underlying immune dysfunction in uremic
patients, the influence of HD on immune dysregulation
and to identify new bio-molecular markers potentially
useful as diagnostic tools and target for new therapeutic
interventions.
Methods
Patients
A total of 50 subjects, after signing informed consent,
were included in the study and divided in a training-
group (n = 26) and a testing-group (n = 24).
A)Training-group
This population was used for the microarray analysis
and to generate the initial hypothesis-generating
genomic model. It included 9 CKD patients on stage
III-IV (mean ± SD of estimated GFR by CKD-EPI
formula: 32.27±14.7 ml/min) and 17 HD patients.
This population was also used for RT-PCR
experiments to validate microarray method. In
addition, 8 healthy subjects (mean age±SD =
51.6±5.8 years and gender: 4 male and 4 female)
were included as control (see Additional file 1:
Figure S1A and B).
B) Testing-group
This group of patients was used to confirm and
validate results obtained by microarray and it
included 11 CKD on stage III-IV (mean ± SD of
estimated GFR by CKD-EPI formula: 30.26±14.89
ml/min) and 13 HD patients.
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three times a week (4–5 hours per session), using syn-
thetic membrane dialyzers. According to the modalities
of the renal replacement therapy, 26 patients were
treated with standard bicarbonate hemodialysis (n:15 in
training-group and n:11 in testing-group) and 4 patients
with on-line post-dilution hemodiafiltration (HDF) (n:2
in training-group and n:2 in the testing-group). For the
HDF patients the substituted volume was approximately
100 ml/min. All patients presented a eKT/V value higher
than 1.3. Moreover, based on several literature evidences
[28,29] and to avoid additional confounding factors
linked to the activation of the inflammatory machinery,
all patients included in our study had native AV fistula.
During the study period, no CKD patients received
dialysis treatment. In addition, all patients suffering from
systemic autoimmune disorders, infectious diseases, dia-
betes, chronic lung diseases, neoplasm, or inflammatory
diseases and patients receiving antibiotics, corticoste-
roids, or non-steroidal anti-inflammatory agents were
excluded. The seven patients with diagnosis of glomer-
ulonephritis as cause of CKD were affected by: Immuno-
globulin A nephropathy (n:3), minimal change disease
(n:2), focal segmental glomerulosclerosis (n:1) and mem-
branous glomerulonephritis (n:1). No patients had symp-
tomatic coronary artery diseases or a family history of
premature cardiovascular diseases. Furthermore, there
were some differences in the pharmacological treatment
between HD and CKD patients. In particular, 86.6% of
HD versus 60% of CKD patients were treated with
recombinant Human Erythropoietin (rHuEPO); 63.3% of
HD versus 5% of CKD patients were supplemented with
intravenous (IV) iron; 40% of HD patients were treated
with paracalcitol, while no CKD patients were treated
with this drug. The main clinical and demographic cha-
racteristics of the subjects included in the training andTable 1 Patient demographics and clinical characteristics
CKD
Number 9
Gender (M/F) 5/4
Age (years) 52.12 ± 5.39
Cause of CKD: GN,ADPKD, renal vascular, desease, unknown 1,3,2,3
Time on dialysis(years) /
BMI (kg/m2) 21.4 ± 1.16
Systolic blood pressure (mmHg) 135 ± 13.22
Diastolyic blood pressure (mmHg) 82 ± 9.43
CRP (ng/ml) 2.65 ± 2.49
Hemoglobin (g/dl) 11.13 ± 1.01
GN: Glomerulonephritis; ADPKD: Autosomal dominant polycystic kidney disease; BM
P-values calculated by T-Test.testing group are summarized in Table 1. The study was
carried out according to Declaration of Helsinki and
approved by the institutional ethical board of the
University Hospital “Policlinico di Bari”, Bari, Italy.
Lymphocyte subset count
For all subjects included in the study, circulating T lym-
phocyte subsets, Natural Killer (NK) cells and B lympho-
cytes were determined using CYTO-STAT tetraCHROME
CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5, CYTO-STAT
tetraCHROME CD45-FITC/CD56-RD1/CD19-ECD/CD3-
PC5 (Beckman Coulter) and the monoclonal antibodies
CD16-PE (Beckman Coulter), CD3-FITC, TCR PAN
gamma/delta. Flow-Count Fluorospheres were used to
determine the absolute cell counts. Red blood cells
were lysed with the COULTER ® ImmunoPrep™ Reagent
System and the remaining white blood cells were
analyzed by a Navios flow cytometry system with the
Navios tetra Software package.
Peripheral blood mononuclear cells (PBMCs) isolation
Twenty ml of whole blood were collected from all sub-
jects included in both training- and testing-group. For
HD patient the biological material was obtained at the
beginning of the second HD session of the week. PBMC
were isolated by density separation over a Ficoll-Paque™
(GE healthcare, Sweden) gradient (460 g for 30 min).
PBMC were washed three times with PBS pH 7.4/1 mM
EDTA (Sigma, Milan, Italy). Cells were then counted
and their viability was assessed by trypan blue exclusion
(>90% PBMC were viable).
RNA extraction and gene expression profiling
For all subjects included in the training-group, total RNA
was isolated by RNeasy mini kit Qiagen (QIAGEN AG,
Basel, Switzerland) following manufacturer’s protocol. TheTraining-group Testing-group
HD P.value CKD HD P.value
17 / 11 13 /
10/7 0.87 6/5 8/5 0.72
52.86 ± 8.63 0.95 51.03 ± 7.59 50.32 ± 9.18 0.95
2,6,4,5 0.90 2,4,3,2 2,4,2,5 0.72
4.98 ± 0.56 / / 5.16 ± 0.75 /
21.8 ± 1.01 0.80 21.9 ± 0.82 21.5 ± 2.23 0.90
136 ± 13.22 0.96 137 ± 9.62 137 ± 12.86 0.98
84 ± 10.01 0.89 82.3 ± 9.85 86 ± 9.67 0.81
3.11 ± 3.45 0.92 2.32 ± 2.69 3.33 ± 3.62 0.85
11.48 ± 1.98 0.90 11.86 ± 1.67 11.38 ± 1.85 0.87
I: Body mass index; CRP: C reactive protein. Values are expressed as mean±SD.
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1000 spectrophotometer) at 260 nm and total RNA
integrity was assessed by electrophoresis using the Agilent
2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). RNA
was, then, processed and hybridized to the GeneChip
Human Genome U133A (n = 5) and Plus (n = 29) oligo-
nucleotide microarray (Affymetrix, Santa Clara, CA,
USA). For our analysis, we used a dataset including 22,283
gene probe sets, representing 12,357 human genes and
3,800 ESTs (Affymetrix; see the manufacturer’s manual for
detailed protocol). We used the default settings of
Affymetrix Microarray Suite software version 5 to calcu-
late scaled gene expression values. Results of the micro-
array experiments are available in Gene Expression
Omnibus (Accession number GSE15072).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA (1 μg) for the 26 patients included in the
training-group was reverse transcribed with the Cloned
AMV first-strand cDNA synthesis kit (Invitrogen) using
Oligo(dT)20 (50 μM) and following the manufacturer’s in-
structions. PCR reactions were performed using primer
designed by the aid of the Primer3 software (http://frodo.
wi.mit.edu). For PTX3 mRNA expression, the primer se-
quences were: forward 5′-CATCCAGTGAGACCAATGA
G-3′ and reverse 5′-GTAGCCGCCAGTTCACCATT-3′.
The conditions of amplification were: 94°C for 20 sec, 58°
C for 20 sec, 70°C for 20 sec for a total of 30 cycles of
amplification. The primers used for IL-15 were forward
5′-GTATTGTAGGAGGCATCGTG-3′ and reverse 5′-
CTCATTACTCAAAGCCACGG-3′. The conditions of
amplification were: 94°C for 20 sec, 57°C for 20 sec, 70°C
for 20 sec for a total of 30 cycles of amplification. β-actin
PCR products were used as control gene. β-actin primer
sequences were forward 5′-ggcatcgtgatggactccg-3′ and re-
verse 5′-gctggaaggtggacagcga-3′. The conditions of ampli-
fication were: 94°C for 20 sec, 65°C for 20 sec, 70°C for 20
sec for a total of 30 cycles of amplification. PCR products
were electrophoretically separated on agarose gels and
stained with ethidium bromide. The density of each band,
corresponding to a specific PCR product, was densitomet-
rically quantified by pixel density using NIH Image J
image software http://rsb.info.nih.gov/ij/. The ratio be-
tween PTX3, IL-15 and β-actin PCR products were used
as indexes of PTX3 and IL-15 gene expression.
Elisa
Because of HLA-G gene was one of the identified genes
by microarray, we decided to measure the soluble form
of HLA-G levels in the plasma of all patients including
in the testing-group. The assay was performed using
commercially available enzyme-linked immunosorbent
assay (ELISA) (BioVendor) according to the manufac-
turer’s instructions.Western blot analysis
Isolated PBMC from 6 CKD and 6 randomly selected
HD patients were lysed in RIPA buffer (1 mM phe-
nylmethylsulphonylfluoride, 5 mM EDTA, 1 mM sodium
orthovanadate,150 mM sodium chloride, 8 μg/ml
leupeptin,1.5% NonidetP-40, 20 mM Tris–HCl pH 7.4).
The lysates were kept on ice for 30 min and centrifuged
at 10000g at 4°C for 10 min. The supernatants were col-
lected and stored at −80°C until use. Aliquots containing
50 μg of proteins from each lysate were subjected to
SDS–PAGE and then electrotransferred onto PVDF
membrane (Biorad). The blot was incubated with anti-
CX3CR1 antibody (Abnova). The membrane was washed
twice in TBS and incubated for one hour at RT with
horseradish peroxidase-conjugated anti-rabbit IgG
(Santa Cruz Biotechnology). The same membrane was
stripped and immunoblotted again with anti-actin
monoclonal antibody (Sigma) and with horseradish
peroxidase-conjugated anti-mouse (Biorad). The ECL-
enhanced chemiluminescence system (Amersham) was
used for detection. Images were quantified by Image
J1.34 Software (http://rsb.info.nih.gov/ij/). The intensity
of band was normalized to the actin signal.
Statistical analysis
Results were expressed as mean ± SD. T-test, ANOVA
and Fisher’s exact test were used to assess differences in
clinical and demographic features. A value of P < 0.05
was considered to be statistically significant.
We selected a total of 1030/22283 gene probe sets
(corresponding to 645 genes) involved in immune re-
sponse pathway according to Gene Ontology (GO,
http://www.geneontology.org). Gene expression values
for the 1030 probe sets, scaled to the target intensity of
2,500, were log transformed. T-TEST, Wilcoxon sum
rank test and distinction calculation (DC) [30] were used
to select probe sets discriminating the two groups of
patients. False discovery rate (FDR) was estimated using
an empirical Bayesian approach based on permutations
(n = 500) and Storey’s q-value [31]. R 2.0.1 statistical
software was used to perform the above analyses. Princi-
pal component analysis (PCA) and hierarchical cluster-
ing were performed using Spotfire DecisionSite 9.0
(www.spotfire.com). To assess the biological relation-
ships among genes, we used the Ingenuity Pathway
Analysis software (IPA, Ingenuity System, Redwood City,
CA, USA; http://www.ingenuity.com). IPA is a know-
ledge database generated from the peer-reviewed scien-
tific publications that enables discovery, visualization
and exploration of functional biological networks in
gene expression data and delineates the functions most
significant to those networks. The 275 differentially
expressed probe sets identified by microarray data, as
discussed below, were used for network analyses.
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queried against all other genes stored in the IPA know-
ledge database to generate a set of networks. Each
Affymetrix probe set ID was mapped to its correspond-
ing gene identifier in the IPA knowledge database. Probe
sets representing genes having direct interactions with
genes in the IPA knowledge database are called ‘focus’
genes, which were then used as a starting point for
generating functional networks. Each generated network
is assigned a score according to the number of differen-
tially regulated focus genes in our dataset. These scores
are derived from negative logarithm of the P indicative
of the likelihood of focus genes being found together in
a network due to random chance. Scores of 4 or higher
have 99.9% confidence level of significance. The resul-
ting networks were represented in graphic format and
adapted for publication.
Results
Analysis of the demographic and clinical features
For all patients included in the study, we did not find
any difference in demographic and clinical features
between CKD and HD patients (Table 1).
Analyzing results from lymphocyte subset count, we
found that, although there were no differences in the
percentage of each cell type between CKD versus HD
patients, both groups showed significantly higher NK
percentage compared to reference ranges (Table 2). This
suggests that NK cells could have a key role in immune
dysfunction in our CKD patients.
Microarray analysis
To identify an immunological transcriptomic profile able
to discriminate CKD and HD patients, we analyzed the
gene-expression profiling of 1030 gene probe sets (corre-
sponding to 645 genes) involved in immune response in
PBMC isolated from 17 HD and 9 CKD on stage III-IV
K-DOQI. According to three independent statistical
algorithms (T-test, Wilcoxon sum rank test and distinc-
tion calculation) and the estimate FDR, we identified
275 gene probe sets discriminating the two groups of pa-
tients (p < 0.0001, FDR = 5%). Among these gene probeTable 2 Lymphocyte subset count distribution in both trainin
Cellular type Training-group
CKD(n = 9) HD(n = 17
Percent of Total CD3 + (T cells) 75.06 ± 10.52 75.65 ± 8.23
Percent of CD3+/CD4 + (Helper T cells) 51.34 ± 8.77 47.12 ± 12.1
Percent of CD3+/CD8+ (Supressor T cells) 22.47 ± 8.35 27.14 ± 9.62
Percent of CD3-/CD16 + CD56+ (NK cells) 17.49 ± 8.07 17.21 ± 8.53
Percent of CD3-/CD19+ (B cells) 7.33 ± 7.35 7.21 ± 3.45
CD4: CD8 Ratio 2.58 ± 1.02 2.08 ± 1.14
Values are expressed as mean±SD. P-values calculated by T-Test.sets, 89 (71 genes, Additional file 1: Table S1A) were up-
regulated and 186 (142 genes, Additional file 1: Table
S1B) were down-regulated in HD compared to CKD pa-
tients. The 2D hierarchical clustering using the 275 gene
probe sets clearly separated patients into 2 distinct
groups and PCA illustrates the degree of discrimination
between the two groups of patients (Figure 1A and B).
Additionally, after including 8 healthy subjects
(NORM) in the analysis, we found that our selected
genes were also able to discriminate uremic patients in
both conservative and hemodialysis treatment from
healthy individuals (Additional file 1: Figure S1A and B).
However, NORM group does not represent a valid
control population because only matched with CKD and
HD groups for few demographic features.
Functional analysis of selected genes identified by
microarray
When the top selected genes up-regulated in HD
patients were analyzed using the IPA software, we found
that in the higher scored network (n = 44, p < 0.0001)
were included genes encoding for biological elements
primarily involved in chronic inflammation (PTX3, IL-15,
IL-8), dendritic cells maturation (CD86), migration and
adhesion of monocytes (CXCL3) (Figure 2A).
Additionally, in the higher scored network (n = 50,
p < 0.0001) built by IPA using the top selected down-
regulated genes in HD patients were included class I
human leukocyte antigen genes (HLA-A, HLA-B, HLA-C,
HLA-E, HLA-F, HLA-G) and those encoding activation
cell surface molecules such as CD40L and FASL
(Figure 2B). For the subsequent parts of the study, we
focused on PTX3, IL-15 and HLA-G.
Validation of microarray using 2 representative genes
involved in the immune response
In order to validate microarray results, pentraxin 3
(PTX-3) and Interleukin-15 (IL-15) mRNA levels were
measured in PBMC of all patients included in the
training-group by PCR. These two genes encode for pro-
teins primary involved in chronic inflammation. Both
mRNA levels were significantly higher in HD comparedg- and testing-group
Testing-group
) p.value CKD(n = 11) HD(n = 13) p.value Ref
0.87 70.05 ± 8.38 74.80 ± 7.68 0.16 66-84
8 0.36 41.46 ± 8.96 46.48 ± 8.69 0.17 43-55
0.23 25.94 ± 7.18 27.11 ± 8.44 0.72 20-32
0.93 21.59 ± 8.59 17.20 ± 7.33 0.19 4-10
0.28 8.45 ± 4.27 7.54 ± 2.64 0.52 6-12
0.94 1.77 ± 0.70 2.00 ± 1/13 0.55 2-3
Figure 1 “Supervised” hierarchical clustering and principal components analysis (PCA) discriminating chronic kidney disease (CKD) and
hemodialysis (HD) treatment. (A) Patients are depicted as vertical columns, with red symbols indicating HD (n = 17) and green indicating CKD
(n = 9) patients. 275 gene probe sets were used for hierarchical clustering. The relative level of gene expression is depicted from lowest (green) to
highest (red) according to the scale shown at the bottom. Cluster A and B include the top statistically significant up-regulated and down-regulated
genes in HD compared to CKD, respectively. (B) PCA plot using the 275 selected gene probe sets discriminating the two groups of patients.
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in line with those obtained by the microarray analysis.
Plasma HLA-G levels in testing-group
Among genes included in the most significant IPA
network built using the significant down-regulated genes
in HD, HLA-G has a pivotal role. This gene encodes for
a protein with inhibitory properties towards major
immune effector cells. In particular, it is able to inhibit
the cytolytic activity and proliferation of NK cells.
Data analysis showed that HD patients had significantly
lower HLA-G plasma level compared to CKD (p = 0.04)
(Figure 4A).
CX3CR1 protein expression
Since HD patients showed down-regulation of HLA-G,
high level of IL-15 (a cytokine that stimulates NK pro-
liferation and cytotoxicity), and inflammatory status as
suggested by elevated level of PTX3, we decided to
evaluate protein expression of chemokine receptor
CX3CR1. CX3CR1 is a highly selective chemokine
receptor and surface marker for cytotoxic effector lym-
phocytes (such as NK cells) and it seems to have a cen-
tral role in several inflammatory diseases.
As shown in Figure 4B, CX3CR1 levels were sig-
nificantly higher in HD compared to CKD patients
(p < 0.01).Discussion
Over the years several studies have tried to clarify the
biological machinery involved in both innate and adap-
tive immune dysfunction in CKD patients in conserva-
tive and HD treatment.
The causes of this condition seem to be primarily
related to: a) an abnormal accumulation of pro-inflamma-
tory cytokines as a consequence of decreased renal elimi-
nation and/or increased generation of uremic toxins; b)
elevated oxidative stress, c) volume overload and d) aug-
mented rate of sepsis [10,11].
Additionally, CKD-related immune dysfunction seems
to be characterized by the coexistence of immune acti-
vation and immune suppression [12]. In this setting,
circulating uremic toxins and microinflammation play a
critical role. However, the exact intricate mechanism
associated to the immune alterations in CKD need to be
more elucidated.
To better understand the biological bases underlying
the immune alterations in patients with severe renal
damages and to assess differences between CKD patients
in pre-dialysis and those undergoing HD treatment, we
used, for the first time, a transcriptomic strategy
combined with classical bio-molecular approaches. This
methodology allowed us to reduce biases due to the
relatively small number of patients enrolled because of
highly selective inclusion/exclusion study criteria (e.g.,
Figure 2 Molecular networks generated by Ingenuity Pathway Analysis using the top selected genes discriminating chronic kidney
disease (CKD) from hemodialysis (HD) patients. Network, algorithmically generated based on the functional and biological connectivity
among genes, was graphically represented as nodes (genes) and edges (the biological relationship between genes). Shaded nodes represented
genes identified by our microarray analysis and others (empty nodes) were those that IPA automatically included because biologically linked to
our genes based on evidence in the literature. Meaning of node shapes and edges are indicated. Red and green shaded genes were those used
for validation by classical biomolecular techniques.
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under-dialyzed patients) and to minimize confounding
factors.
Furthermore, our study was performed using an oligo-
nucleotide microarray technology able to evaluate simul-
taneously the expression of more than 15,000 genes.
However, to take full advantage of the opportunities
offered by this high throughput method, it is necessary
to manage, integrate and interpret a huge amount of
data correctly. Thus, we decided to use a pathway ana-
lysis to focus our research on candidate genes known to
be associated with immune response in order to reduce
the false positive rate and the puzzling factors not
directly associated with the aims of our research.
Microarray analysis revealed that 213 immunological
genes were able to discriminate CKD from HD patients.
In particular, 71 genes resulted up-regulated and 142
down-regulated in HD compared to CKD. Althoughthese differences were primarily related to the trans-
criptomic changes induced by the dialysis treatment, we
cannot exclude that the different pharmacological
treatments may have contributed to increase the
immune-transcriptomic differences between CKD and
HD patients. In fact, as extensively described [32-35],
some medications (e.g., rHuEPO, VDR activators and IV
iron), may influence both inflammatory and immune
response. It is plausible that the deregulation of some
immunological genes in our HD patients (for example
the up-regulation of CD86 and the down-regulation of
CD40/CD40LG) may have been, at least partially deter-
mined by the chronic use of rHuEPO and/or
paracalcitol. However, at the state of art, there is a lack
of pharmacogenomics study in this field. Further studies
are warranted to address this important point.
Interestingly, the biological network generated by
Ingenuity Pathway Analysis software using the top HD
Figure 3 PTX3 and IL15 gene expression in peripheral blood mononuclear cells by RT-PCR in chronic kidney disease (CKD) and
hemodialysis (HD) patients. Dot-plot represents PTX3 and IL15 gene expression assessed by RT-PCR in PBMC from 9 CKD and 17 HD patients.
The bars indicate the median value. As depicted, HD patients showed significantly higher level of both genes compared to CKD patients. P values
were calculated by t-test.
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Interleukin 15 (IL-15) had an important functional role.
PTX3 encodes for an acute phase protein produced by
monocytes, macrophages and endothelial cells [36] and,
as reported by several reports, its expression is high in
plasma of patients with sepsis [37], acute myocardial
infarction [38] and severe atherosclerosis [39].
Our results, confirming previous reports [40,41],
indicate that HD enhances PTX3 levels and point out
that this inflammatory biomarker may be a valuable
candidate to measure chronic microinflammatory stateFigure 4 HLA-G and CX3CR1 plasma protein expression by ELISA and
disease (CKD) and hemodialysis (HD) patients. A) The histogram repres
13 HD patients. HD patients presented significantly lower HLA-G level com
CX3CR1 protein level in total cell lysates of 6 CKD and 6 HD patients. CX3C
< 0.01). On the right it is reported a representative western blotting experimin our nephrology/dialyzed patients. In fact, in our
subset of patients, C reactive protein (CRP) was not
different between CKD and HD probably because less
sensitive and specific biomarker for this patient
population.
Then, we observed that IL-15 was highly expressed in
our HD patients compared to CKD. This gene encodes
for a 13 kDa cytokine produced by macrophages and
other cell types in response to inflammatory and infect-
ive stimuli that shares many biological activities with IL-
2 inducing the activation of JAK/STAT pathway andWestern blotting, respectively (A and B) in chronic kidney
ents the mean ± SD of HLA-G levels assessed by ELISA in 11 CKD and
pared to CKD (p = 0.04); B) Histogram represents the mean ± SD of
R1 levels were significantly higher in HD compared to CKD patients (p
ent. P values were calculated by t-test.
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activation [42-45].
On the other hand, among the genes down-regulated
in HD patients, we identified those encoding for the
Human Leukocyte Antigen (HLA)-G. The HLA-G
primary transcript encodes a transmembrane protein
with a molecular weight of 39 kDa that may be classified
as a nonclassical major histocompatibility complex class
I molecule that differs from other HLA class I molecules
with regard to its low polymorphism, restricted tissue
distribution, slow turnover, immunosuppressive proper-
ties and limited peptide diversity [46-48].
Under physiological conditions, the production of
HLA-G protein is restricted to trophoblast [49], thymic
epithelial cells [50], first-trimester placental chorionic
blood vessel endothelial cells [51], and IFN-γ-treated
mononuclear phagocytes [52].
However, the up-regulation of this protein can be
detected in several pathological conditions such as trans-
plantation, tumors, viral infections and autoimmune
diseases [53-57].
HLA-G gene expression is tightly regulated at both the
transcriptional and post-transcriptional levels and through
epigenetic mechanisms, which include DNA methylation
and histone deacetylation [58]. In addition, different re-
searchers have shown that HLA-G mRNA expression
does not systematically result in the presence of the pro-
tein [59,60]. This implies a tight post-transcriptional regu-
lation of HLA-G gene expression.
HLA-G possesses the capability to bind inhibitory
receptors such as the Immunoglobulin-like transcript-2
and −4 (ILT2, ILT4) and the Killer Immunoglobulin-like
Receptor (KIR)2DL4/CD158d with inhibitory effects [61,62].
In particular, HLA-G may have a direct immune-
inhibitory function through blocking effector cells and
indirect immune-inhibitory activity by regulatory cell gen-
eration. Via the direct inhibitory functions, HLA-G is able
to inhibit the cytolytic activity and proliferation of NK [63],
the antigen-specific cytolytic functions of α/β and γ/δ T
lymphocytes [63,64], the alloproliferative response of T cells
[65,66], the proliferation of NK and T cells [66] and the
DCs maturation [67]. Therefore, the lower HLA-G expres-
sion in HD patients suggests that innate immune effector
cells could be activated in this subset of patients confirming
some reports showing that long-time dialysis enhances NK
cytotoxic activity [68,69].
Furthermore, since HD patients showed down-
regulation of HLA-G, high level of IL-15, and inflamma-
tory status as suggested by increased level of PTX3, we
decided to evaluate protein expression of chemokine
receptor CX3CR1.
CX3CR1 is the fractalkine (CX3CL1) receptor and is
expressed in cytotoxic effector lymphocytes such as NK,
cytotoxic T lymphocytes (CTL) and γ/δ T cells whichpossess high levels of intracellular perforin and gran-
zyme B [70] suggesting that its activation could be
involved in migration of the cells to sites of inflamma-
tion [71]. Moreover, this receptor is up-regulated during
chronic inflammation [72] and it is increased in mono-
cytes, T lymphocytes and NK cells present in severe
atherosclerosis and ruptured coronary plaques in
patients with unstable angina pectoris [73].
As shown in Figure 4B, CX3CR1 levels were signifi-
cantly higher in HD compared to CKD patients (p < 0.01).Conclusions
Although with the presence of some limitations, such as
small number of patients included in the microarray ana-
lysis, impossibility of controlling all variables potentially
able to influence the transcriptomic profile (e.g., etio-
logical cause of CKD, drugs, diet) and absence of clinically
matched healthy subjects, our study shows, for the first
time, that HD patients present a different immune-pattern
compared to CKD patients in conservative treatment.
Among the selected genes, some of them encode for im-
portant biological elements involved in proliferation/acti-
vation of cytotoxic effector lymphocytes and in the
immune-inflammatory cellular machinery. Additionally,
this study reveals new potential diagnostic bio-markers
and useful targets for innovative therapeutic interventions.Additional file
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